



## Metal-Based Anticancer Drugs

Guest Editors:

**Prof. Dr. Vladimir Arion**

Institute of Inorganic Chemistry,  
University of Vienna, Währinger  
Str. 42, 1090 Vienna, Austria

**Prof. Dr. Debbie Crans**

Department of Chemistry,  
Colorado State University, Fort  
Collins, CO 80523, USA

**Prof. Dr. Ignacio E. Leon**

Centro de Química Inorgánica  
(CEQUINOR), CONICET-UNLP, La  
Plata, Buenos Aires, Argentina

Deadline for manuscript  
submissions:

**closed (30 June 2022)**

### Message from the Guest Editors

Dear Colleagues,

The use of metal complexes as anticancer agents revolutionized cancer treatment more than fifty years ago with the discovery of cisplatin, *cis*-[PtCl<sub>2</sub>(NH<sub>3</sub>)<sub>2</sub>]. Further research led to clinical use of other platinum drugs, namely, carboplatin and oxaliplatin. The main deficiencies of the platinum-based drugs are their severe side effects and drug resistance. New metal-based anticancer drugs including essential and nonessential metals that have a different mode of action might be able to broaden the spectrum of treatable cancers, reduce toxic side effects, and overcome platinum resistance. The concept of selective targeting of cancer cells remains a challenge. Many new approaches to the design of innovative metal-based anticancer drugs are currently emerging. These include prodrugs, dual or multi-action prodrugs, etc. To enhance the efficacy of new metal-based drugs, prodrug and targeting strategies, as well as suitable drug delivery approaches, are being developed (design and synthesis of new ligands, nanocarriers, etc.). This Special Issue aims to highlight the progress in the field of development of new metal-based anticancer drugs.

*Guest Editors*





an Open Access Journal by MDPI

## Editor-in-Chief

**Prof. Dr. Duncan H. Gregory**  
School of Chemistry, University of  
Glasgow, University Avenue,  
Glasgow G12 8QQ, UK

## Message from the Editor-in-Chief

Inorganic chemistry remains a lynchpin of modern chemistry, not only embracing the function and reactivity of combinations of most elements of the periodic table, but also providing a footing for studies of materials, catalysts, drugs, fuels and industrial chemicals. Arguably, the role and reach of inorganics in society have never been as great as today. Adventurous research at the heart and at the extremes of inorganic chemistry is vital to further advances and *Inorganics* offers authors the opportunity to publish exciting new research in an open access format.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), CAPlus / SciFinder, and other databases.

**Journal Rank:** JCR - Q2 (*Chemistry, Inorganic and Nuclear*) / CiteScore - Q2 (*Inorganic Chemistry*)

## Contact Us

---

*Inorganics* Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
www.mdpi.com

mdpi.com/journal/inorganics  
inorganics@mdpi.com  
X@inorganics\_MDPI